Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck accelerates subcutaneous Keytruda rollout to protect cancer drug's dominance as IV patent nears 2028 expiry.

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr. Joerg Koglin, Merck’s senior vice president and head of general medicine and ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

RFK Jr.'s call to ban TV advertisements for prescription drugs reignited support for a bipartisan bill that would mandate the retail prices of drugs be included in TV ads.

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.